Results 21 to 30 of about 196,164 (338)

Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.

Journal of the American Society of Nephrology, 2021
BACKGROUND A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is lacking ...
F. Scolari, Elisa Delbarba, D. Santoro, L. Gesualdo, A. Pani, N. Dallera, Laila-Yasmin Mani, M. Santostefano, S. Feriozzi, M. Quaglia, G. Boscutti, A. Ferrantelli, C. Marcantoni, P. Passerini, R. Magistroni, F. Alberici, G. Ghiggeri, C. Ponticelli, P. Ravani   +18 more
semanticscholar   +1 more source

Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2021
Importance The current standard induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis is the combination of high-dose glucocorticoids and cyclophosphamide or rituximab.
S. Furuta, D. Nakagomi, Yoshihisa Kobayashi, M. Hiraguri, T. Sugiyama, K. Amano, T. Umibe, H. Kono, K. Kurasawa, Y. Kita, R. Matsumura, Y. Kaneko, K. Ninagawa, K. Hiromura, S. Kagami, Y. Inaba, H. Hanaoka, K. Ikeda, H. Nakajima   +18 more
semanticscholar   +1 more source

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Haematologica, 2018
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia.
Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Ünal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, Véronique Leblond   +16 more
doaj   +1 more source

Rituximab for the treatment of multiple sclerosis: a review

Journal of Neurology, 2021
In the last decades, evidence suggesting the direct or indirect involvement of B cells on multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on the efficacy and safety of B-cell-depleting therapies from several studies has
C. Chisari, Eleonora Sgarlata, S. Arena, Simona Toscano, M. Luca, F. Patti   +5 more
semanticscholar   +1 more source

Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease

Neurology, 2022
Background and Objectives Rituximab is used widely for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-IgG–associated disease (MOGAD); however, data regarding the effectiveness and safety
Paula Barreras, E. Vasileiou, Angeliki G. Filippatou, K. Fitzgerald, M. Levy, C. Pardo, S. Newsome, E. Mowry, P. Calabresi, Elias S. Sotirchos   +9 more
semanticscholar   +1 more source

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

Journal of Hematology & Oncology, 2022
Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies.
Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang   +17 more
doaj   +1 more source

Rituximab

Indian Pediatrics, 2011
Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells.
Anupama, Borker, Narendra, Choudhary
openaire   +2 more sources

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2019
BACKGROUND Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have ...
T. Shanafelt, X. V. Wang, N. Kay, C. Hanson, S. O'brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina K Singh, M. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman   +20 more
semanticscholar   +1 more source

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

New England Journal of Medicine, 2019
BACKGROUND B-cell anomalies play a role in the pathogenesis of membranous nephropathy. B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine for inducing and maintaining a complete or partial remission of proteinuria
F. Fervenza, G. Appel, S. Barbour, B. Rovin, R. Lafayette, N. Aslam, J. A. Jefferson, P. Gipson, Dana V. Rizk, J. Sedor, J. Simon, E. McCarthy, P. Brenchley, S. Sethi, C. Avila-Casado, H. Beanlands, J. Lieske, D. Philibert, Tingting Li, L. Thomas, Dolly F Green, L. Juncos, Lada Beara-Lasic, S. Blumenthal, Amy N. Sussman, S. Erickson, M. Hladunewich, P. Canetta, L. Hebert, N. Leung, J. Radhakrishnan, H. Reich, S. Parikh, D. Gipson, Dominic Lee, Bruno R. da Costa, P. Jüni, D. Cattran   +37 more
semanticscholar   +1 more source

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis

Neurology: Neuroimmunology & Neuroinflammation, 2021
Background and Objectives To determine the real-world use of rituximab in autoimmune encephalitis (AE) and to correlate rituximab treatment with the long-term outcome.
F. Thaler, Luise Zimmermann, S. Kammermeier, C. Strippel, M. Ringelstein, A. Kraft, K. Sühs, Jonathan Wickel, C. Geis, R. Markewitz, Christian Urbanek, C. Sommer, K. Doppler, Loana Penner, J. Lewerenz, Rosa Rössling, Carsten Finke, H. Prüss, Nico Melzer, K. Wandinger, F. Leypoldt, T. Kümpfel   +21 more
semanticscholar   +1 more source